Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials

@article{Lagan2018MyoinositolSR,
  title={Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials},
  author={Antonio Simone Lagan{\`a} and Amerigo Vitagliano and Marco Noventa and Guido Ambrosini and Rosario D'Anna},
  journal={Archives of Gynecology and Obstetrics},
  year={2018},
  volume={298},
  pages={675-684}
}
PurposeTo evaluate whether oral myo-inositol supplementation (MI) is able to reduce the amount of gonadotropins (GA) and the length of controlled ovarian hyperstimulation (SL) in both Polycystic Ovarian Syndrome (PCOS) and non-PCOS women undergoing in vitro fertilization (IVF).MethodsWe performed a systematic review (PROSPERO ID: CRD42017069439) of randomized controlled trials (RCTs). We searched articles published in English between January 1985 to August 2017, using the combination of the… Expand
Effect of myo-inositol supplementation on ICSI outcomes among poor ovarian responder patients: a randomized controlled trial.
TLDR
Treatment of poor responders with myo-inositol from one month before starting ICSI cycle continuing until ovulation trigger can improve fertilization rate and embryo quality, and may enhance the cumulative pregnancy rate in poor responders. Expand
Myo-Inositol’s Role in Assisted Reproductive Technology: Evidence for Improving the Quality of Oocytes and Embryos in Patients With Polycystic Ovary Syndrome
TLDR
There is a lack of statistically significant evidence to support the use of MI in enhancing the quality of oocyte and/or embryo in PCOS; however, many of the reviewed studies have shown a trend toward the improvement of embryo quality in women with PCOS after MI supplementation. Expand
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach
TLDR
Given their functions, inositols are an attractive treatment option for PCOS, although well-designed studies on spontaneous and non-spontaneous fertility are needed. Expand
Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies
TLDR
Myo-inositol is effective in normalizing ovarian function, improving oocyte and embryo quality in PCOS, however further evaluations by large multicentre randomized controlled trials are needed to assess the clinical pregnancy and live birth rates in ART. Expand
Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
TLDR
It is quite surprising to find that inositol-based treatments for PCOS seem to be randomly chosen and are often combined with useless or even counterproductive molecules, all of which can weaken myo-inositol's efficacy. Expand
Inositols in Polycystic Ovary Syndrome: An Overview on the Advances
TLDR
The physiological activities of MI and DCI dictate the dosages and timing of inositol supplementation in the treatment of PCOS and new data on the use of alpha-lactalbumin to boost inositl absorption is discussed. Expand
Laparoscopic Ovarian Drilling Reduces Testosterone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio and Improves Clinical Outcome in Women with Polycystic Ovary Syndrome
TLDR
LOD significantly reduced testosterone and LH/FSH ratio in ovulatory and conceived groups, and the menstrual cycle became regular, and hirsutism and acne were reduced after LOD in women with PCOS. Expand
Treatment with d-chiro-inositol and alpha lipoic acid in the management of polycystic ovary syndrome
TLDR
The association of d-chiro-inositol and alpha lipoic acid improves menstrual cycle length, restoring ovulation in the majority of women, and insulin sensitivity improved in women with IR only, confirming that in presence of IR the d- Chiro inositol has a role in restoring the insulin action overcoming the inactivity of epimerase. Expand
Inositol for the prevention of gestational diabetes: a systematic review and meta-analysis of randomized controlled trials
TLDR
ISLs administration during pregnancy appears to be safe and may represent a novel strategy for GDM prevention, in particular, the double administration of Myo-inositol 2 g per day may improve the glycemic homeostasis and may reduce GDM rate and preterm delivery rate. Expand
Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)
TLDR
The evidence in the literature supports the beneficial effects of myo-inositol in both female and male reproduction, warranting clinical use of MI in assisted reproductive treatment (ART). Expand
...
1
2
3
...

References

SHOWING 1-10 OF 37 REFERENCES
Effect of myo-inositol and melatonin versus myo-inositol, in a randomized controlled trial, for improving in vitro fertilization of patients with polycystic ovarian syndrome
TLDR
Myo-Inositol and melatonin proved to be efficient predictors for positive IVF outcomes, correlating with high oocyte quality, and routinely MI and M supplementation in the IVF protocols was integrated. Expand
Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
TLDR
Myo-inositol supplementation was insufficient to improve oocyte quality and pregnancy rates for women with PCOS undergoing intracytoplasmic sperm injection and future studies of appropriate dose, size and duration of DCI are vital to clarify its the role in the management of PCOS. Expand
Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial.
TLDR
It is suggested that myoinositol may be useful in the treatment of PCOS patients undergoing ovulation induction, both for its insulin-sensitizing activity, and its role in oocyte maturation. Expand
Myo-inositol rather than D-chiro-inositol is able to improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
TLDR
The data show that, in PCOS patients having a normal insulin response, myo- inositol treatment rather than D-chiro-inositol is able to improve oocyte and embryo quality during ovarian stimulation protocols. Expand
Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study
TLDR
The findings suggest that the addition of myo-inositol to folic acid in non PCOS-patients undergoing multiple follicular stimulation for in-vitro fertilization may reduce the numbers of mature oocytes and the dosage of rFSH whilst maintaining clinical pregnancy rate. Expand
Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials
TLDR
An overview on the clinical outcomes of the MYO use as a treatment to improve ovarian function and metabolic and hormonal parameters in women with PCOS is provided. Expand
Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.
TLDR
Treatment with myo-inositol and folic acid, but not folic Acid alone, reduces germinal vesicles and degenerated oocytes at ovum pick-up without compromising total number of retrieved oocytes in polycystic ovary syndrome patients. Expand
Myo-inositol therapy for poor-responders during IVF: a prospective controlled observational trial
TLDR
The results suggest that MI therapy in poor responders results in an increased of the number of oocytes recovered in MII and of the Gonadotropin Ovarian Sensitivity Index (OSI), suggesting a MI role in improving ovarian response to gonadotropins. Expand
Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET
TLDR
Myoinositol supplement increase clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET, and may improve the quality of embryos, and reduce the unsuitable oocytes and required amount of stimulation drugs. Expand
Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
  • P. Artini, O. M. Di Berardino, +4 authors V. Cela
  • Medicine
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2013
TLDR
Myo-inositol administration improves reproductive axis functioning in PCOS patients reducing the hyperinsulinemic state that affects LH secretion, and insulin sensitivity, expressed as glucose-to-insulin ratio and HOMA index resulted significantly improved after 12 weeks of treatment. Expand
...
1
2
3
4
...